Last reviewed · How we verify
Dapsone plus Tretinoin Gel
Dapsone reduces inflammation and bacterial growth while tretinoin promotes skin cell turnover and normalizes keratinization to treat acne and related inflammatory skin conditions.
Dapsone reduces inflammation and bacterial growth while tretinoin promotes skin cell turnover and normalizes keratinization to treat acne and related inflammatory skin conditions. Used for Acne vulgaris.
At a glance
| Generic name | Dapsone plus Tretinoin Gel |
|---|---|
| Also known as | Aczone Gel 5% plus Retin-A Micro Gel 0.1% Pump |
| Sponsor | Bausch Health Americas, Inc. |
| Drug class | Combination topical acne agent (sulfone + retinoid) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Dapsone is a sulfone antibiotic with anti-inflammatory properties that inhibits neutrophil function and reduces inflammatory mediators, while tretinoin is a retinoid that increases cell turnover, reduces comedone formation, and normalizes sebaceous gland function. Together, they address both the inflammatory and comedonal components of acne vulgaris and related dermatological conditions.
Approved indications
- Acne vulgaris
Common side effects
- Erythema
- Dryness
- Peeling
- Irritation
- Photosensitivity
Key clinical trials
- A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dapsone plus Tretinoin Gel CI brief — competitive landscape report
- Dapsone plus Tretinoin Gel updates RSS · CI watch RSS
- Bausch Health Americas, Inc. portfolio CI